Corrigendum

Corrigendum to “Curcumin Analogue CA15 Exhibits Anticancer Effects on HEp-2 Cells via Targeting NF-κB”

Jian Chen,1,2 Linlin Zhang,3 Yilai Shu,1 Liping Chen,2 Min Zhu,2 Song Yao,2 Jiabing Wang,2 Jianzhang Wu,2 Guang Liang,2 Haitao Wu,1 and Wulan Li2,4

1Departments of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose and Throat Hospital, Fudan University, Shanghai, China
2Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
3Department of Stomatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
4College of Information Science and Computer Engineering, School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China

Correspondence should be addressed to Wulan Li; lwlwzmu@163.com

Received 1 November 2017; Accepted 8 November 2017; Published 28 December 2017

Copyright © 2017 Jian Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Curcumin Analogue CA15 Exhibits Anticancer Effects on HEp-2 Cells via Targeting NF-κB” [1], the cell line HEp-2 used in the study had been reported to be contaminated by HeLa, a cervical cancer cell line. Therefore, the study can only prove that the compound CA15 has antitumor effects, not antihuman laryngeal carcinoma.

References
